Skip to main content

Aldeyra Therapeutics to Participate in Upcoming Conferences

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra or the Company), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in the following investor conferences:

  • Berenberg US CEO Conference
    Format: Analyst-Hosted Fireside Chat
    Date: Wednesday, November 10, 2021
    Time: 10:00 a.m. ET
    Note: A live and recorded webcast of this event will be available on the Investors & Media page of the Company’s website at https://ir.aldeyra.com/. The recorded webcast will be archived and available for 90 days.
  • Eyecelerator@AAO 2021
    Format: Retina Showcase Presentation
    Date: Thursday, November 11, 2021
    Time: 1:05 p.m. CT (2:05 p.m. ET)
  • Jefferies London Healthcare Conference
    Format: Analyst-Hosted Fireside Chat
    Time: Available On Demand Beginning at 8:00 a.m. GMT (3:00 a.m. ET) Thursday, November 18, 2021
    Note: A webcast of this event will be available on the Investors & Media page of the Company’s website at https://ir.aldeyra.com/. The recorded webcast will be archived and available for 90 days.
  • Ophthalmology Day at BTIG
    Format: Analyst-Hosted Fireside Chat
    Date: Tuesday, November 30, 2021
    Time: 1:00 p.m. ET

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc. is a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases. Two of the Company’s lead product candidates, reproxalap and ADX-629, target RASP, which are pre-cytokine, systems-based mediators of inflammation. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The Company’s clinical pipeline also includes ADX-2191 (methotrexate for intravitreal injection), a drug candidate in Phase 3 testing for the prevention of proliferative vitreoretinopathy. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

Contacts:

Corporate Contact:
Joshua Reed
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218
jreed@aldeyra.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.